February 20, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is ...

(Reuters) -Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human ...

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

And with Janssen deciding to axe its hepatitis C collaboration with Achillion last month, Merck's decision comes as no surprise. The combinations axed by Merck are MK-3682B (grazoprevir+ruzasvir ...

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey · Reuters Michael Erman and Mariam Sunny Updated Tue, Feb 4, 2025, 7:21 AM 3 min read ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...